Established and experimental treatments for sickle cell disease

Haematologica

Volumn 89, Issue 3, 2004, Pages 348-356

  De Franceschi, Lucia ^a   Corrocher, Roberto ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Cation transport; Endothelium; Fetal hemoglobin; Hydroxyurea; Red cell dehydration

Indexed keywords

CALCIUM ACTIVATED POTASSIUM CHANNEL; HEMOGLOBIN F; HEMOGLOBIN S; HYDROXYUREA;

CATION TRANSPORT; CELL INTERACTION; CLINICAL FEATURE; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; HEMOGLOBIN SYNTHESIS; HUMAN; KINETICS; NONHUMAN; PATHOPHYSIOLOGY; POLYMERIZATION; REVIEW; SICKLE CELL ANEMIA;

ANEMIA, SICKLE CELL; ANIMALS; ANTISICKLING AGENTS; ERYTHROCYTE MEMBRANE; ERYTHROCYTES; HEMOGLOBIN, SICKLE; HUMANS; ION CHANNELS;

EID: 2942749947     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. Eaton WA, Hofrichter J. Hemoglobin S gelation and sickle cell disease. Blood 1987;70:1245-52.
2. Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Prot Chem 1990;40:63-279.
3. Nagel RL and Platt OS. General pathophysiology of sickle cell anemia. In: Disorders of Hemoglobin. Steinberg MH, Forget BG, Higgs DR, Nagel RL, editors. Cambridge University Press. 2001. p. 494-526.
4. Stuart MJ, Setty BN. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood 1999;94:1555-60.
5. Noguchi CT, Rodgers GP, Schechter AN. Intracellular polymerization. Disease severity and therapeutic predictions. Ann NY Acad Sci 1989;565:75-82.
6. Nagel RL, Bookchin RM, Labie D, Wajcman H, Isaac-Sadeye WA, Honig GR. Structural basis for the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci USA 1979;76:670-2.
7. Eaton WA, Hofrichter J. The biophysics of sickle cell hydroxyurea therapy. Science 1995;268:1142-3.
8. Hebbel RP. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 1997;100:S83-6.
9. de Jong K, Larkin SK, Styles LA, Bookchin RM, Kuypers FA. Characterization of the phosphatidylserine-exposing subpopulation of sickle cells. Blood 2001;98:860-6.
10. de Jong K, Emerson RK, Butler J, Bastacky J, Mohandas N, Kuypers FA. Short survival of phosphatidylserine-exposing red blood cells in murine sickle cell anemia. Blood 2001;98:1577-84.
11. Kuypers FA. Phospholipid asymmetry in health and diseased. Curr Opin Haematol 1998;5:122-31.
12. Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood 1992;79:2154-63.
13. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999;340:1021-30.
14. Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest 1998;101:1899-904.
15. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-44.
16. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-22.
17. Weiner DL, Brugnara C. Hydroxyurea and sickle cell disease. A chance for every patient. JAMA 2003;289:1692-4.
18. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia. JAMA 2003;289:1645-51.
19. Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001;294:2368-71.
20. Edington GM, Lehmann H. Expression of the sickle-cell gene in Africa. Br Med J 1955;1:1308-11.
21. Watson J, Stahman AW, Bilello FP. Significance of paucity of sickle cells in newborn negro infants. Am J Med Sci 1948;215:419-23.
22. Nagel RL, Bookchin RM, Labie D, Wajcman H, Isaac-Sadeye WA, Honig GR. Structural basis for the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci USA 1979;76:670-2.
23. Charache S, Dover G, Smith K, Talbot CC, Jr, Moyer M, Boyer SH. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the γ-δ-β globin gene complex. Proc Natl Acad Sci USA 1983;80:4842-6.
24. Ley TJ, DeSimone J, Noguchi CT, Turner PH, Schechter AN, Heller P, Nienhuis AW. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 1983;62:370-80.
25. Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Ewa Witkowska H, et al. A short-term trial of butyrate to stimulate fetal-globin- gene expression in the β-globin disorders. N Engl J Med 1993;328:81-6.
26. Sher GD, Ginder GD, Little J, Yang S, Dover GJ, Olivieri NF. Extended therapy with intravenous arginine butyrate in patients with β- hemoglobinopathies. N Engl J Med 1995;332:1606-10.
27. Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994;84:339-43.
28. Blau CA, Constantoulakis P, Shaw CM, Stamatoyannopoulos G. Fetal hemoglobin induction with butyric acid: Efficacy and toxicity. Blood 1993;81:529-37.
29. Humphries RK, Dover G, Young NS, Moore JG, Charache S, Ley T, et al. 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin. J Clin Invest 1985;75:547-57.
30. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood 1997;89:1078-88.
31. Osarogiagbon UR, Choong S, Belcher JD, Vercellotti GM, Paller MS, Hebbel RP. Reperfusion injury pathophysiology in sickle transgenic mice. Blood. 2000;96:314-20.
32. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest 2000;106:411-20.
33. Hillery C, Holzman S, Franciosi J, Ou J, Ou Z, Mohandas N, et al. Changes in hsp90-eNOS interactions following hypoxia-induced acute lung injury in a murine model of sickle cell disease. Blood 2002;100:29[abstract].
34. Belcher J, Marker P, Hebbel R, Vercellotti G. Inflammatory response in transgenic mouse models of human sickle cell anemia. Blood 2000;90: 2574[abstract].
35. De Franceschi L, Baron A, Scarpa A, Adrie C, Janin A, Barbi S, et al. Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. Blood 2003;102:1087-96.
36. Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med 1980;302:992-5.
37. Sugihara K, Sugihara T, Mohandas N, Hebbel RP. Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells. Blood 1992;80:2634-42.
38. Wick TM, Moake JL, Udden MM, McIntire LV. Unusually large von Willebrand factor multimers preferentially promote young sickle and non sickle erythrocyte adhesion to endothelial cells. Am J Hematol 1993;42:284-92.
39. Swerlick RA, Eckman JR, Kumar A, Jeitler M, Wick TM. α4β1- Integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium. Blood 1993;82:1891-9.
40. Gee BE, Platt OS. Sickle reticulocytes adhere to VCAM-1. Blood 1995;85:268-74.
41. Brittain HA, Eckman JR, Swerlick RA, Howard RJ, Wick TM. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion. Blood 1993;81:2137-43.
42. Joneckis CC, Ackley RL, Orringer EP, Wayner EA, Parise LV. Integrin α4β1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood 1993;82:3548-55
43. Adragna NC, Fonseca P, Lauf PK. Hydroxyurea affects cell morphology cation transport and red blood cell adhesion in cultured vascular endothelial cells. Blood 1994;83:553-60.
44. Sato K, Akaike T, Sawa T, Miyamoto Y, Suga M, Ando M, et al. Nitric oxide generation from hydroxyurea via copper-catalyzed peroxidation and implications for pharmacological actions of hydroxyurea. Jpn J Cancer Res 1997;88:1199-204.
45. Jiang J, Jordan SJ, Barr DP, Gunther MR, Maeda H, Mason RP. In vivo production of nitric oxide in rats after administration of hydroxyurea. Mol Pharmacol 1997;52:1081-6.
46. Xu YP, Mull CD, Bonifant CL, Yasaki G, Palmer EC, Shields H, et al. Nitrosylation of sickle cell hemoglobin by hydroxyurea. J Org Chem 1998;63:6452-3.
47. Glover RE, Ivy ED, Orringer EP, Maeda H, Mason RP. Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Mol Pharmacol 1999;55:1006-10.
48. Nahavandi M, Wyche MQ, Perlin E, Tavakkoli F, Castro O. Nitric oxide metabolites in sickle cell anemia patients after oral administration of hydroxyurea: hemoglobinopathy. Hematology 2000;5:335-9.
49. Gladwin MT, Shelhamer JH, Ognibene FP, Pease-Fye ME, Nichols JS, Link B, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol 2002;116:436-44.
50. Huang J, Zou Z, Kim-Shapiro DB, Ballas SK, King SB. Hydroxyurea analogues as kinetic and mechanistic probes of the nitric oxide producing reactions of hydroxyurea and oxyhemoglobin. J Med Chem 2003;46:3748-53.
51. Nahavandi M, Tavakkaii F, Wyche MQ, Perlin E, Winter WP, Castro O. Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroyurea. Br J Haematol 2002;119:855-7.
52. Cokic VP, Smith RD, Beleslin-Cokic BB, Njoroge JM, Miller JL, Gladwin MT, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 2003;111:231-9.
53. King BS. A role for nitric oxide in hydroxyurea-mediated fetal hemoglobin induction. J Clin Invest 2003;111:171-2.
54. Papassotiriou I, Stamoulakatou A, Voskaridou E, Stamou E, Loukopoulos D. Hydroxyurea induced erythropoietin secretion in sickle cell syndromes may contribute in their HbF increase. Blood 1998;92:160[abstract].
55. Kim-Shapiro DB, King SB, Bonifant CL, Ballas SK. Hydroxyurea reacts with sickle cell hemoglobin to form methemoglobin and other minor species. Blood 1997;9028b[abstract].
56. Lockamy VL, Huang J, Shields H, Ballas SK, King SB, Kim-Shapiro DB. Urease enhances the formation of iron nitrosyl hemoglobin in the presence of hydroxyurea. Biochim Biophys Acta 2003;1622:109-16.
57. Billett HH, Kim K, Fabry ME, Nagel RL. The percentage of dense red cells does not predict incidence of sickle cell painful crisis. Blood 1986;68:301-3.
58. Serjeant GR, Serjeant BE, Milner PF. The irreversibly sickled cell; a determinant of hemolysis in sickle cell anemia. Br J Haematol 1969;17:527-33.
59. Fabry ME, Mears JG, Patel P, Schaefer-Rego K, Carmichael LD, Martinez G, et al. Dense cells in sickle cell anemia: the effects of gene interaction. Blood 1984;64:1042-6.
60. Horiuchi K, Stephens MJ, Adachi K, Asakura T, Schwartz E, Ohene-Frempong K. Image analysis studies of the degree of irreversible deformation of sickle cells in relation to cell density and Hb F level. Br J Haematol 1993;85:356-64.
61. Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood 1992;79:2154-63.
62. Lawrence C, Fabry ME, Nagel RL. Red cell distribution width parallels dense red cell disappearance during painful crises in sickle cell anemia. J Lab Clin Med 1985;105:706-10.
63. Kaul DK, Fabry ME, Nagel RL. Vaso-occlusion by sickle cells: evidence for selective trapping of dense red cells. Blood 1986;68:1162-6.
64. Kaul DK, Chen D, Zhan J. Adhesion of sickle cells to vascular endothelium is critically dependent on changes in density and shape of the cells. Blood 1994;83:3006-17.
65. Bookchin RM, Etzion Z, Sorette M, Mohandas N, Skepper JN, Lew VL, et al. Identification and characterization of a newly recognized population of high-Na+, low-K+, low-density sickle and normal red cells. Proc Natl Acad Sci USA 2000;97:8045-50.
66. Holtzclaw JD, Jiang M, Yasin Z, Joiner CH, Franco RS. Rehydration of high-density sickle erythrocytes in vitro. Blood 2002;100:3017-25.
67. Franco RS, Yasin Z, Lohmann JM, Palascak MB, Nemeth TA, Weiner M, et al. The survival characteristics of dense sickle cells. Blood 2000;96:3610-7.
68. Rosa RM, Bierer BE, Thomas R, Stoff JS, Kruskall M, Robinson S, et al. A study of induced hyponatremia in the prevention and treatment of sickle-cell crisis. N Engl J Med 1980;303:1138-43.
69. Lew VL, Hockaday A, Sepulveda MI, Somlyo AP, Somlyo AV, Ortiz OE, et al. Compartmentalization of sickle-cell calcium in endocytic inside-out vesicles. Nature 1985;315:586-9.
70. Rhoda MD, Apovo M, Beuzard Y, Giraud F. Ca2+ permeability in deoxygenated sickle cells. Blood 1990:2453-8.
71. Murphy E, Berkowitz LR, Orringer E, Levy L, Gabel SA, London RE. Cytosolic free calcium in sickle red blood cells. Blood 1987;69:1469-74.
72. Gardos G. The function of calcium in the potassium permeability of human erythrocytes. Biochim Biophys Acta 1958;30:653-4.
73. Brugnara C, Armsby CC, De Franceschi L, Crest M, Euclaire MF, Alper SL. Ca(2+)-activated K+ channels of human and rabbit erythrocytes display distinctive patterns of inhibition by venom peptide toxins. J Membr Biol 1995;147:71-82.
74. Ishii TM, Silvia C, Hirschberg B, Bond CT, Adelman JP, Maylie J. A human intermediate conductance calcium-activated potassium channel. Proc Natl Acad Sci USA 1997;94:11651-6.
75. Brugnara C, De Franceschi L, Alper SL. Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J Clin Invest 1993;92:520-6.
76. Lew VL, Ortiz OE, Bookchin RM. Stochastic nature and red cell population distribution of the sickling-induced Ca2+ permeability. J Clin Invest 1997;99:2727-3.
77. McGoron AJ, Joiner CH, Palascak MB, Claussen WJ, Franco RS. Dehydration of mature and immature sickle red blood cells during fast oxygenation/ deoxygenation cycles: role of KCl cotransport and extracellular calcium. Blood 2000;95:2164-8.
78. Lew VL, Etzion Z, Bookchin RM. Dehydration response of sickle cells to sickling-induced Ca(++) permeabilization. Blood 2002;99:2578-85.
79. De Franceschi L, Saadane N, Trudel M, Alper SL, Brugnara C, Beuzard Y. Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease. J Clin Invest 1994;93:1670-6.
80. De Franceschi L, Brugnara C, Rouyer-Fessard P, Jouault H, Beuzard Y. Formation of dense erythrocytes in SAD mice exposed to chronic hypoxia: evaluation of different therapeutic regimens and of a combination of oral clotrimazole and magnesium therapies. Blood 1999;94:4307-13.
81. Brugnara C, Armsby CC, Sakamoto M, Rifai N, Alper SL, Platt O. Oral administration of clotrimazole and blockade of human erythrocyte Ca(++)-activated K+ channel: the imidazole ring is not required for inhibitory activity. J Pharmacol Exp Ther 1995;273:266-72.
82. Rifai N, Sakamoto M, Law T, Platt O, Mikati M, Armsby CC, et al. HPLC measurement, blood distribution, and pharmacokinetics of oral clotrimazole, potentially useful antisickling agent. Clin Chem 1995;41:387-91.
83. Brugnara C, Gee B, Armsby CC, Kurth S, Sakamoto M, Rifai N, et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1996;97:1227-34.
84. Stocker JW, De Franceschi L, McNaughton-Smith GA, orrocher R, Beuzard Y, Brugnara C. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood 2003;101:2412-8.
85. Rigdon G, Stocker JW, McNaughton-Smith G, Hull H, Leese P. A phase 1 safety, pharmacokinetic, and pharmacodynamic study of ascending, single, oral doses of ICA-17043, a novel Gardos channel inhibitor for the treatment of sickle cell disease. Blood 2000;96:21b [abstract].
86. Morris CR, Kuypers FA, Larkin S, Sweeters N, Simon J, Vichinsky EP, et al. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol 2000;111:498-500.
87. Romero JR, Suzuka SM, Nagel RL, Fabry ME. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood 2002;99:1103-8.
88. Gillen CM, Brill S, Payne JA, Forbush B 3rd. Molecular cloning and functional expression of the K-Cl cotransporter from rabbit, rat, and human. A new member of the cation-chloride cotransporter family. J Biol Chem 1996;271:16237-44.
89. Shmukler BE, Brugnara C, Alper SL. Structure and genetic polymorphism of the mouse KCC1 gene. Biochem Biophys Acta 2000;93417:1-9.
90. Vu TQ, Payne JA, Copenhagen DR. Localization and developmental expression patterns of the neuronal K-Cl cotransporter (KCC2) in the rat retina. J Neuroscience 2000;20:1414-23.
91. Williams JR, Sharp JW, Kumari VG, Wilson M, Payne JA. The neuron-specific K-Cl cotransporter, KCC2. Antibody development and initial characterization of the protein. J Biol Chem 1999;274:12656-64.
92. Mercado A, Song L, Vazquez N, Mount DB, Gamba G. Functional comparison of the K-Cl cotransporters KCC1 and KCC4. J Biol Chem 2000;275:30326-34.
93. Brugnara C, Kopin AS, Bunn HF, Tosteson DC. Regulation of cation content and cell volume in erythrocytes from patients with homozygous hemoglobin C disease. J Biol Chem 1985;75:1608-17.
94. Brugnara C, Bunn HF, Tosteson DC. Regulation of erythrocyte cation and water content in sickle cell anemia. Science 1986;232:388-90.
95. Canessa M, Spalvins A, Nagel RL. Volume-dependent and NEM-stimulated K+, Cl- transport is elevated in oxygenated SS, SC and CC human red cells. FEBS Lett 1986;200:197-202.
96. Hall AC, Ellory JC. Evidence for the presence of volume-sensitive KCl transport in 'young' human red cells. Biochim Biophys Acta 1986;858:317-20.
97. Brugnara C, Tosteson DC. Cell volume, K transport, and cell density in human erythrocytes. Am J Physiol 1987;252:C269-76.
98. Canessa M, Romero JR, Lawrence C, Nagel RL, Fabry ME. Rate of activation and deactivation of K:Cl cotransport by changes in cell volume in hemoglobin SS, CC and AA red cells. J Membr Biol 1994;142:349-62.
99. Fabry ME, Romero JR, Suzuka SM, et al. Hemoglobin C in transgenic mice with full mouse globin knockouts. Blood 1998;92:330a[abstract].
100. Vitoux D, Beuzard Y, Brugnara C. The effect of hemoglobin A and S on the volume-and pH-dependence of K-Cl cotransport in human erythrocyte ghosts. J Memb Biol 1999;167:233-40.
101. Jennings ML, Schulz RK. Okadaic acid inhibition of K-Cl cotransport. Evidence that protein dephosphorylation is necessary for activation of transport by either cell swelling or N-ethylmaleimide. J Gen Physiol 1991;97:799-818.
102. De Franceschi L, Fumagalli L, Olivieri O, Corrocher R, Lowell CA, Berton G. Deficiency of src family kinases Fgr and Hck results in activation of erythrocyte K/Cl cotransport. J Clin Invest 1997;99:220-7.
103. Bize I, Munoz P, Canessa M, Dunham PB. Stimulation of membrane serine-threonine phosphatase in erythrocytes by hydrogen peroxide and staurosporine. Am J Physiol 1998;274:C440-6.
104. Franco RS, Thompson H, Palascak M, Joiner CH. The formation of transferrin receptor-positive sickle reticulocytes with intermediate density is not determined by fetal hemoglobin content. Blood 1997;90:3195-203.
105. Franco RS, Palascak M, Thompson H, Joiner CH. KCl cotransport activity in the light versus dense transferrin receptor positive sickle reticulocytes. J Clin Invest 1995;95:2573-80.
106. Olukoga AO, Adewoye HO, Erasmus RT, Adedoyin MA. Erythrocyte and plasma magnesium in sickle-cell anaemia. East Afr Med J 1990;67:348-54.
107. De Franceschi L, Bachir D, Galacteros F, Tchernia G, Cynober T, Alper S, et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1997;100:1847-52.
108. De Franceschi L, Beuzard Y, Jouault H, Brugnara C. Modulation of erythrocyte potassium chloride cotransport, potassium content, and density by dietary magnesium intake in transgenic SAD mouse. Blood 1996;88:2738-44.
109. De Franceschi L, Bachir D, Galacteros F, Tchernia G, Cynober T, Neuberg D, et al. Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. Br J Haematol 2000;108:248-89.
110. de Montalembert M, Roudot-Thoraval F, Galacteros F, De Franceschi L, Brugnara C, Beuzard Y. Treatment with oral magnesium pidolate in children with sickle cell disease. Blood 2002;100:1760 [abstract].
111. Brousseou DC, Panepinto JA, Hillery CA, Scott JP. The effect of intravenous magnesium sulfate on length of stay for children hospitalized with sickle cell disease. Blood 2003;100:2815[abstract].
112. Bennekou P. K+-valinomycin and chloride conductance of the human red cell membrane. Influence of the membrane protonophore carbonylcyanide m-chlorophenylhydrazone. Biochem Biophys Acta 1984;776:1-9.
113. Bennekou P. The feasibility of pharmacological volume control of sickle cells is dependent on the quantization of the transport pathways. A model study. J Theoret Biol 1999;196:129-37.
114. Bennekou P, Pedersen O, Moller A, Christophersen P. Volume control in sickle cells is facilitated by the novel anion conductance inhibitor NS1652. Blood 2000;95:1842-8.
115. Bennekou P, De Franceschi L, Pedersen O, Lian L, Asakura T, Evans G, et al. Treatment with NS3623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach to sickle cell disease. Blood 2001;97:1451-7.
116. Tosteson DC, Shea E, Darling RC. Potassium and sodium of red blood cells in sickle cell anemia. J Clin Invest 1952;31:406-11.
117. Tosteson DC, Carlsen E, Dunham ET. The effects of sickling on ion transport. I. Effect of sickling on potassium transport. J Gen Physiol 1955;39:31-53.
118. Tosteson DC. The effects of sickling on ion transport. II. The effect of sickling on sodium and cesium transport. J Gen Physiol 1955;39:55-67.
119. Berkowitz LR, Orringer EP. Passive sodium and potassium movements in sickle erythrocytes. Am J Physiol 1985;249:C208-14.
120. Joiner CH. Studies on the mechanism of passive cation fluxes activated by deoxygenation of sickle cells. Progr Clin Biol Res 1987;240:229-35.
121. Joiner CH, Dew A, Ge DL. Deoxygenation-induced cation fluxes in sickle cells: relationship between net potassium efflux and net sodium influx. Blood Cells 1988;13:339-58.
122. Joiner CH. Deoxygenation-induced cation fluxes in sickle cells: II. Inhibition by stilbene disulfonates. Blood 1990;76:212-20.
123. Clark MR, Rossi ME. Permeability characteristics of deoxygenated sickle cells. Blood 1990;76:2139-45
124. Bookchin RM, Ortiz OE, Lew VL. Evidence for a direct reticulocyte origin of dense red cells in sickle cell anemia. J Clin Invest 1991;87:113-24
125. Joiner CH, Jiang M, Claussen WJ, et al. Dipyridamole inhibits sickling-induced cation fluxes in sickle red blood cells. Blood 2001;97:3976-83.
126. Adams-Graves P, Kedar A, Koshy M, Steinberg M, Veith R, Ward D, et al. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: A pilot study. Blood 1997;90:2041-6.
127. Orringer EP, Casella JF, Ataga KI, Koshy M, Adams-Graves P, Luchtman-Jones L, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA 2001;286:2099-106.
128. Kaul DK, Tsai HM, Liu XD, Nakada MT, Nagel RL, Coller BS. Monoclonal antibodies to a Vβ3 (7E and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood 2000;95:368-74.
129. Barabino GA, Liu XD, Ewenstein BM, Kaul DK. Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result in improved hemodynamic behavior. Blood 1999;93:1422-9.
130. Solovey AA, Solovey AN, Harkness J, Hebbel RP. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 2001;97:1937-41.
131. Mosseri M, Bartlett-Pandite AN, Wenc K, Isner JM, Weinstein R. Inhibition of endothelium-dependent vasorelaxation by sickle erythrocytes. Am Heart J 1993;126:338-46.
132. Weinstein R, Zhou M, Bartlett-Pandite A, Wenc K. Sickle erythrocytes inhibit human endothelial cell DNA synthesis. Blood 1990;76:2146-52.
133. Roberts JD Jr, Fineman JR, Morin FC 3rd, Shaul PW, Rimar S, Schreiber MD, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med. 1997;336:605-610
134. Atz AM, Wessel DL. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology 1997;87:988-99
135. Fox-Robichaud A, Payne D, Hasan SU, Ostrovsky L, Fairhead T, Reinhardt P, et al. Inhaled NO as a viable antiadhesive therapy for ischemia/reperfusion injury of distal microvascular beds. J Clin Invest 1998;101:2497-250
136. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991;83:2038-47
137. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res. 1989;65:1-21
138. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991;338:1173-4
139. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993;328:399-40
140. Lopez BL, Barnett J, Ballas SK, Christopher TA, Davis-Moon L, Ma X. Nitric oxide metabolite levels in acute vaso-occlusive sickle-cell crisis. Acad Emerg Med 1996;3:1098-103.
141. Qureshe M, Swerdlow P, Girgis R. Decreased exhaled nitric oxide (NO) in patients with sickle cell disease. Blood 2000;90:2571 [abstract].
142. Gladwin MT, Schechter AN, Shelhamer JH, Pannell LK, Conway DA, Hrinczenko BW, et al. Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity. J Clin Invest 1999;104:937-45.
143. Cannon RO 3rd, Schechter AN, Panza JA, Ognibene FP, Pease-Fye ME, Waclawiw MA, et al. Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J Clin Invest 2001;108:279-87.
144. Morris CR, Vichinsky EP, van Warderdam J, Machado L, Kepka-Lenhart D, Morris SM jr, et al. Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. J Pediatr Hematol Oncol 2003;25:629-34.